Liquidia Co. (NASDAQ:LQDA – Get Free Report) insider Rajeev Saggar sold 6,249 shares of the business’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the sale, the insider now owns 270,388 shares of the company’s stock, valued at approximately $3,185,170.64. The trade was a 2.26 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Rajeev Saggar also recently made the following trade(s):
- On Friday, October 18th, Rajeev Saggar sold 2,526 shares of Liquidia stock. The shares were sold at an average price of $11.19, for a total transaction of $28,265.94.
Liquidia Price Performance
Shares of NASDAQ LQDA traded down $0.40 during trading hours on Tuesday, reaching $11.36. The stock had a trading volume of 552,977 shares, compared to its average volume of 728,753. The business’s fifty day moving average is $11.18 and its two-hundred day moving average is $11.02. The company has a market cap of $961.48 million, a price-to-earnings ratio of -6.97 and a beta of 0.23. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $16.99.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Several equities analysts have recently issued reports on LQDA shares. Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of Liquidia in a report on Thursday, January 9th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Lifesci Capital initiated coverage on shares of Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective for the company. Scotiabank initiated coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target for the company. Finally, Wells Fargo & Company initiated coverage on shares of Liquidia in a report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Liquidia has a consensus rating of “Buy” and a consensus target price of $25.38.
Get Our Latest Analysis on LQDA
About Liquidia
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Further Reading
- Five stocks we like better than Liquidia
- Trading Stocks: RSI and Why it’s Useful
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Want to Profit on the Downtrend? Downtrends, Explained.
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.